Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. [electronic resource]
Producer: 20200615Description: 1-12 p. digitalISSN:- 2473-4276
- Antineoplastic Agents -- adverse effects
- Cost-Benefit Analysis
- Decision Making
- Decision Trees
- Hepatitis B -- diagnosis
- Hepatitis B virus -- genetics
- Humans
- Immunosuppressive Agents -- adverse effects
- Mass Screening
- Models, Theoretical
- Neoplasms -- complications
- Quality of Life
- Quality-Adjusted Life Years
- SEER Program
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.